Skip navigation
Home
News
Products
about IR-World
Team
Customers
Partner
Contact
DE
EN
Communicators
are winners!
Text der Meldung
More News
10.01.2024
Defence’s AccuTOX® Impairs Lung Cancer Growth
12.12.2023
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with Accutox(R)
14.11.2023
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
07.11.2023
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
25.10.2023
Defence’s AccuTOX® and Antigen Cross-Presentation: Discovery Leads towards the Development of a Groundbreaking Platform
18.10.2023
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
17.10.2023
Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
10.10.2023
Defence Announces Peer-Reviewed Publication of its Preclinical Data on Accum® as an Anti-Cancer Molecule in the Journal of Cancer Science
25.09.2023
Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
12.09.2023
Defence Therapeutics Inc.: Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
Previous
1
2
3
4
5
6
7
Next
Last